Pfizer buys Metsera for $10B
Digest more
NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...
Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...
The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...
2don MSN
Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition
Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...
“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...
At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...
Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...
Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 ...
That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...
On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback